Vor Biopharma Inc. (NYSE:VOR) Receives $11.36 Consensus Price Target from Brokerages

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) has received an average recommendation of "Buy" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $11.36.

Several analysts have commented on the stock. JMP Securities reiterated a "market outperform" rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Wedbush reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of Vor Biopharma in a research note on Monday, December 9th. Robert W. Baird decreased their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating on the stock in a research note on Friday, November 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $17.50 target price on shares of Vor Biopharma in a report on Tuesday, December 10th.

Hedge Funds Weigh In On Vor Biopharma

A number of large investors have recently added to or reduced their stakes in VOR. Renaissance Technologies LLC grew its position in shares of Vor Biopharma by 48.0% in the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company's stock worth $495,000 after buying an additional 160,642 shares during the last quarter. Rosalind Advisors Inc. acquired a new position in shares of Vor Biopharma during the third quarter worth $54,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vor Biopharma during the 2nd quarter valued at $63,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Vor Biopharma in the 2nd quarter worth $53,000. Finally, Exchange Traded Concepts LLC grew its stake in Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company's stock worth $116,000 after buying an additional 48,017 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Price Performance

Shares of NYSE:VOR traded down $0.04 during trading on Tuesday, hitting $0.98. 297,100 shares of the company's stock were exchanged, compared to its average volume of 512,493. The business's 50-day simple moving average is $0.81 and its 200 day simple moving average is $0.92. The company has a market cap of $67.04 million, a price-to-earnings ratio of -0.59 and a beta of -0.37. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $3.14.

Vor Biopharma (NYSE:VOR - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). On average, sell-side analysts anticipate that Vor Biopharma will post -1.55 EPS for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.